Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | GLS | O94925 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4118148 | 0.81 | HTR2C (0.38) | RIPK1HTR2CSLC6A4GBA1MGLL | |
| SCHEMBL3650693 | 0.79 | CLK1 (0.36) | RIPK1HTR2CSLC6A4MGLLGLS | |
| SCHEMBL5890773 | 0.73 | RIPK1 (0.63) | RIPK1HTR2CSLC6A4GLSRAB9A | |
| SCHEMBL3651194 | 0.72 | SIRT2 (0.37) | LMNA | |
| SCHEMBL23201921 | 0.70 | RIPK1 (0.43) | RIPK1HTR2CSLC6A4GBA1GLS | |
| SCHEMBL15973941 | 0.69 | PLOD2 (0.47) | RIPK1RAB9ANAMPTCYP3A4LMNA | |
| SCHEMBL3701898 | 0.68 | HTR2C (0.49) | HTR2CSLC6A4 | |
| SCHEMBL11480586 | 0.66 | RIPK1 (0.39) | RIPK1HTR2CSLC6A4GBA1GLS | |
| SCHEMBL6121860 | 0.65 | RIPK1 (0.61) | RIPK1GBA1RAB9ACYP3A4 | |
| SCHEMBL31407151 | 0.65 | SSTR4 (0.41) | RIPK1HTR2CSLC6A4MGLLGLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | RIPK1 4203/4885HTR2C 2565/4885SLC6A4 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.